Cumberland Pharmaceuticals Inc. Stock price

Equities

CPIX

US2307701092

Pharmaceuticals

Delayed Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
1.79 USD -1.10% Intraday chart for Cumberland Pharmaceuticals Inc. -4.79% -0.09%
Sales 2022 42.01M Sales 2023 39.55M Capitalization 26.7M
Net income 2022 -5M Net income 2023 -6M EV / Sales 2022 0.8 x
Net Debt 2022 1.2M Net Debt 2023 107K EV / Sales 2023 0.68 x
P/E ratio 2022
-5.88 x
P/E ratio 2023
-4.07 x
Employees 91
Yield 2022 *
-
Yield 2023
-
Free-Float 54.85%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Cumberland Pharmaceuticals Inc.'s Equity Buyback Plan announced on May 13, 2010. CI
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Cumberland Pharmaceuticals Inc., 2023 Earnings Call, Mar 05, 2024
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cumberland Pharmaceuticals Seeks Acquisitions CI
Transcript : Cumberland Pharmaceuticals Inc., Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q3 EPS $0.02 MT
Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q3 Revenue $10.1M MT
Tranche Update on Cumberland Pharmaceuticals Inc.'s Equity Buyback Plan announced on May 13, 2010. CI
Cumberland Pharmaceuticals Inc. Announces New Antimicrobial Agents and Chemotherapy Detaining the Results of the First Clinical Study Investigating the Safety and Pharmacokinetics of Vibativ®? Injection in Children 2 to 17 Years of Age CI
Cumberland Pharmaceuticals Inc. Announces New Publication in Antimicrobial Agents and Chemotherapy Detaining the Safety and Pharmacokinetics of Vibativ Injection in Children 2 to 17 Years of Age CI
Correction to SEC Fines Article DJ
SEC Fines 5 Public Companies, Insiders Over Reporting Failures DJ
SEC Charges Corporate Insiders for Failing to Timely Report Transactions and Holdings CI
More news

Latest transcript on Cumberland Pharmaceuticals Inc.

1 day-1.10%
1 week-4.79%
Current month-15.96%
1 month-15.96%
3 months-5.79%
6 months-4.79%
Current year-0.09%
More quotes
1 week
1.70
Extreme 1.6994
1.83
1 month
1.70
Extreme 1.6994
2.23
Current year
1.70
Extreme 1.6994
2.36
1 year
1.43
Extreme 1.43
2.36
3 years
1.43
Extreme 1.43
7.51
5 years
0.00
Extreme 0
7.51
10 years
0.00
Extreme 0
7.96
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 99-01-06
Director of Finance/CFO 67 18-12-31
Compliance Officer 67 02-12-31
Members of the board TitleAgeSince
Director/Board Member 59 22-07-14
Chief Executive Officer 65 99-01-06
Director/Board Member 66 17-01-17
More insiders
Date Price Change Volume
24-03-27 1.79 +4.68% 4,501
24-03-26 1.71 0.00% 11,825
24-03-25 1.71 -5.52% 12,847
24-03-22 1.81 0.00% 21,653
24-03-21 1.81 -3.72% 16,554

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever, Kristalose for oral solution, a prescription laxative, for the treatment of constipation, and Omeclamox-Pak, oral, for the treatment of Helicobacter pylori infection and related duodenal ulcer disease. Its brands also include Sancuso transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia, and Vibativ injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock Cumberland Pharmaceuticals Inc. - Nasdaq